Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Sera Prognostics (SERA) Form 4: Director Mansoor Raza Mirza reported the automatic sale of 225 Class A common shares on 08/05/2025 at $2.50 per share ($563 total value). The shares were sold exclusively to satisfy tax-withholding obligations triggered by the vesting of restricted stock units; the transaction was executed under the company’s mandatory “sell-to-cover” program and was not discretionary. Following the sale, Mirza’s direct beneficial ownership stands at 58,702 shares. No derivative securities were involved and no changes were made to option or RSU positions.
The filing reflects a routine administrative sell-to-cover with de minimis dollar value relative to company market capitalization and Mirza’s remaining stake. There are no indications of broader insider sentiment, strategic shifts, or liquidity concerns.
Sera Prognostics, Inc. (SERA) submitted a Form 144 notice covering the planned sale of 225 Class A common shares through Morgan Stanley Smith Barney on 05 Aug 2025. At the indicated aggregate market value of $563, the transaction is de-minimis relative to the company’s 37,672,784 shares outstanding (≈0.0006%).
The seller—identified in subsequent tables as Mansoor Raza Mirza—previously sold 447 shares over the past three months for total gross proceeds of $980. The shares to be sold were acquired via RSU vesting on the planned sale date, implying the disposal is likely routine compensation-related rather than a directional view on the business. The filer affirms possession of no undisclosed material information, satisfying Rule 144 requirements.
Aberdeen Group plc and its U.S. affiliate abrdn Inc. have filed a Schedule 13G disclosing a passive ownership stake in Sera Prognostics (SERA).
- Shares owned: 2,227,367 Class A common shares.
- Ownership percentage: 6.07% of the outstanding class as of 30 Jun 2025.
- Voting & dispositive power: 0 shares held with sole power; all 2,227,367 shares held with shared voting and dispositive power by both reporting entities.
- Reporting parties: Aberdeen Group plc (UK parent, classified as a Holding Company – “HC”) and abrdn Inc. (US subsidiary, classified as Corporation & Investment Adviser – “CO, IA”).
- Intent: Certification states the position is held in the ordinary course of business and is not intended to influence or control the issuer.
- Structure: Aberdeen Group plc → abrdn Holdings Ltd. → abrdn Inc.; the U.S. adviser holds the shares for underlying clients.
The filing indicates that a sizable institutional investor has surpassed the 5 % threshold, triggering disclosure under Rule 13d-1(b). No changes to company control or strategic direction are signaled.
Sera Prognostics Chief Commercial Officer Dyaarl Lee Anderson Jr. received significant equity compensation on June 23, 2025, consisting of two components:
- 67,114 Restricted Stock Units (RSUs) with a four-year vesting schedule: - 25% vests on June 10, 2026 - Remaining 75% vests quarterly over three years
- 102,534 Stock Options with strike price of $1.87: - 25% vests on June 10, 2026 - Remaining 75% vests monthly over three years
Both grants require continued service with the company. The equity awards suggest a long-term retention strategy for the Chief Commercial Officer position, with zero-cost RSUs balanced against performance-based stock options. The relatively low strike price of $1.87 indicates potential upside opportunity in the company's growth prospects.